BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Cancer / Oncology

Exicure Secures Australian Patent for Dual-Target Cancer Therapy Approach

Exicure, Inc. announced that the Australian Patent Office has issued Patent No. 2018388302, titled "GPCR Heteromer Inhibitors and Uses Thereof." ...

March 14, 2025 | News

Gleneagles Hospital Hong Kong Becomes Asia’s First Private Hospital to Offer Histotripsy for Liver Cancer Treatment

Gleneagles Hospital Hong Kong (Gleneagles) is excited to be the first private hospital in Asia to offer Histotripsy treatment, the transformative...

March 11, 2025 | News

RiboX Doses First Patient in Pioneering Circular RNA Therapy Trial for Radiation-Induced Xerostomia

RiboX Therapeutics Ltd. (RiboX), a pioneering biopharmaceutical company, focused on discovering and developing fully engineered circular RNA therapeutics,&...

March 10, 2025 | News

Everest Medicines Doses First Patient with AI-Driven Personalized mRNA Cancer Vaccine EVM16 in Landmark Clinical Trial

The first patient has been dosed with EVM16 at Peking University Cancer Hospital, marking a major milestone as Everest's proprietary AI-based tumor neoan...

March 07, 2025 | News

CStone Pharmaceuticals Advances CS5001 with Phase Ib Trial Application in Australia for First-Line DLBCL Treatment

Phase Ib trial to evaluate CS5001 in combination with R-CHOP as a first-line treatment for diffuse large B-cell lymphoma (DLBCL), aiming to reshape ...

March 06, 2025 | News

Alphamab Oncology and CSPC Dose First Patient in Phase III Trial of JSKN003 for HER2-Positive Breast Cancer

Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that the first patient has...

February 28, 2025 | News

Innovent’s Ipilimumab NDA Accepted by China’s NMPA with Priority Review for MSI-H/dMMR Colon Cancer

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...

February 25, 2025 | News

MGI Partners with Oncoclínicas&Co to Expand Genomic Testing and Oncology Diagnostics in Brazil

MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technologies that drive innovation in life science, established a partnersh...

February 25, 2025 | News

Akeso, Summit Therapeutics, and Pfizer Join Forces to Advance Ivonescimab-ADC Combinations in Solid Tumor Trials

Akeso, Inc. announced that its partner on ivonescimab, Summit Therapeutics Inc. has entered into a clinical trial collaboration with Pfizer Inc...

February 25, 2025 | News

Akeso Begins Phase III Trial of Ivonescimab for First-Line Treatment of Advanced Triple-Negative Breast Cancer

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced the company has successfully enrolled the first patient in its multicenter, ran...

February 24, 2025 | News

Harbour BioMed and Insilico Medicine Partner to Accelerate AI-Driven Antibody Discovery

Harbour BioMed, a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on...

February 21, 2025 | News

Nona Biosciences Partners with UAB to Advance B Cell Research Using H2L2 Harbour Mice®

Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to I™), announced a licensing agreement with ...

February 20, 2025 | News

Roche and Yemaachi Launch The African Cancer Atlas to Advance Precision Oncology Across Africa

Roche has signed as the founding partner to initiate the consortium which will generate genomic and clinical data from up to 7,500 African cancer pat...

February 19, 2025 | News

NERLYNX® Approved in Thailand for Early and Advanced HER2+ Breast Cancer Treatment

NERLYNX® (neratinib) has been approved as a single agent for the treatment of early-stage HER2+ breast cancer, and in combination with capecitab...

February 18, 2025 | News

Stay Connected